R&D channel feed – Endpoints News

R&D channel feed

Aeterna Zentaris shares eviscerated by its latest late-stage drug disaster

9 years ago

Following Vertex pact, Parion strikes another rich collaboration — this time with Shire

9 years ago

Little Neurotrope makes some big claims on another failed Alzheimer’s study, but shares collapse

9 years ago

Tom Lynch outlines his comeback strategy for Bristol-Myers’ badly bruised R&D organization

9 years ago

Not so crazy now: Biotech’s most closely watched unicorn just produced its first clear snapshot of human efficacy data

9 years ago

Pfizer wins a “breakthrough” title for ALK/ROS1 contender lorlatinib after hustling into PhIII

9 years ago

An ailing AstraZeneca kicks two drugs out of the pipeline and an ex-drug partner’s share price is blasted

9 years ago

Scangos left Biogen in style, taking a final $17.7M compensation package for one last, disappointing year

9 years ago

Stymied on Nasdaq, Apple Tree’s Braeburn sinks another short putt with late-stage implant

9 years ago

Buzz: Teva Chairman Sol Barer is getting busy with a top-to-bottom rehab plan for a wounded giant

9 years ago

Medicines Co., Alnylam prepare to throw the dice on a late-stage effort to leapfrog PCSK9 giants

9 years ago

Novartis takes a $200M hit to write off a flop as execs spell out a cautious R&D strategy

9 years ago

Blitzed by trial failures, OncoMed axes half its staff and retrenches around PhI drugs

9 years ago

Best in class? Eli Lilly claims a lead role awaits its CDK 4/6 drug abemaciclib after PhIII success

9 years ago

Facing a payer backlash over sticker shock, Biogen fields positive data on Spinraza for children 2-12

9 years ago

EASL Roundup: Bristol-Myers and NGM post a positive look at PhII NASH data; Genfit details PhIII delay

9 years ago

Gilead offers a glimpse at hard data to back up its $600M investment in Nimbus’ NASH drug

9 years ago

A second wave of checkpoint inhibitors is swelling fast, with speedy BeiGene leaping into a pivotal trial

9 years ago

AbbVie, Enanta post stellar hep C PhIII data, but no one is cheering

9 years ago

AbbVie grapples with another setback as 2 PhIII trials for its PARP veliparib flop

9 years ago

Ultragenyx, Kyowa Hakko Kirin plan a date with the FDA after positive PhIII for X-linked hypophosphatemia

9 years ago

Bristol-Myers preps second checkpoint/cancer vax combo study under its $1B Bavarian Nordic pact

9 years ago

Novartis ties up with the virtual biotech Parvus to try a new approach on Type 1 diabetes

9 years ago

A final flop signals the bitter end to Circassia’s big plans for allergy R&D

9 years ago

First page Previous page 301 302 303304305 306 307 Next page Last page